|
|
Article: Neurocrine Biosciences Announces Positive Phase II Results With NBI-34060 In Patients With Chronic Insomnia.
- Article from:
- PR Newswire
- Article date:
- July 17, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Efficacy Has Been Achieved in Both Primary and Secondary Endpoints for Sleep
Initiation and Sleep Maintenance;
Pivotal Phase III Studies to Begin Q4, 2001
SAN DIEGO, July 17 /PRNewswire/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced dose related positive efficacy results with all four doses of NBI-34060 in a Phase II study in the target population of Chronic Insomnia. This study was a randomized, multi-center, double-blind, placebo and active-drug controlled, six-way crossover dose response study in 59 enrolled patients with chronic primary insomnia, designed to evaluate efficacy and to select doses to proceed into ...